Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Thursday, September 03, 2026

Notes On Instrument APIs Critiques I Delegated to Claude

›
In my previous post about the Model Hardware Standard from Anthropic , I mentioned some exploration I've been running on instrument API...
Monday, August 31, 2026

Model Hardware Standard: What Is It? Seriously, That's What I'm Asking.

›
Anthropic, the company behind Claude, announced a new initiative called the Model Hardware Standard (MHS).   It's a way to enable intell...
1 comment:
Thursday, August 27, 2026

Recombination-Based Autonomous Protein Structure-Function Search

›
An interesting preprint showed up last week in the autonomous agent-driven experimentation space - an area I'm paid to be very intereste...
1 comment:
Thursday, August 20, 2026

SIMB Notebook: The Frontiers of Protein Engineering

›
The Society for Industrial Microbiology (SIMB) annual meeting in Austin the first week of the month was great fun.  I caught up with two War...
Tuesday, August 18, 2026

HiFi's Not Very Pacific Waters

›
PacBio had a major shakeup early this month. First came a large round of layoffs, which caught several individuals who were very much the fa...
5 comments:
Monday, August 03, 2026

When PCR Gives You Lemons...

›
I wish to highlight an interesting new preprint from a group at Danish Technical University which explores the schmutz in PCR reactions, d...
1 comment:
Tuesday, July 28, 2026

Dad Had Manuals, I Have An Agent

›
My father was a very methodical person, and that particularly applied when he decided to purchase the second IBM PC clone to appear on the m...
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.